New drug to benefit cancer patients undergoing chemotherapy

August 10, 2017 by David Stacey, University of Western Australia
New drug to benefit cancer patients undergoing chemotherapy
Credit: University of Western Australia

Researchers at The University of Western Australia have developed an innovative approach to prevent one of the most serious side-effects of chemotherapy, known as myelosuppression.

In a study published today in Science Translational Medicine, the researchers reveal that myelosuppression can be prevented in laboratory models by a drug called quizartinib. Myelosuppression is caused when chemotherapy kills cells in the bone marrow that produce all our .

Lead researcher Professor Wally Langdon, from UWA's School of Biomedical Sciences, said myelosuppression caused complications such as fatigue, dizziness, bruising, haemorrhage and potentially fatal infections.

"This means that patients often need to limit their chemotherapy dosage and frequency in order to avoid these complications, which can then compromise the effectiveness of cancer treatment," Professor Langdon said.

He said current methods of managing myelosuppression were costly and of limited effectiveness.

"This simple approach to prevent chemotherapy-induced myelosuppression has come from research where we discovered that a single dose of quizartinib puts blood-producing cells in the bone marrow to sleep for a short period of time," Professor Langdon said.

"In other words, quizartinib converts these normally flourishing cells into a state of dormancy. We found that this transient period of dormancy provided significant protection to the bone marrow and when the awakened, at a time when the chemotherapy was no longer active, they resumed their task of producing healthy blood cells."

The researchers found that quizartinib did not put the to sleep, and as a result these cells were still eliminated by chemotherapy while the normal cells were protected.

Professor Langdon said an important feature of the treatment was that most cancer cells were not affected by quizartinib.

"This means a priming dose of quizartinib before chemotherapy could be used to help treat a wide range of cancers," he said.

"It is hoped that these findings will lead to clinical trials to determine the extent of the beneficial effects that quizartinib may provide for cancer patients receiving ."

Explore further: New antibody uses 1-2 punch to potentially treat blood cancers

More information: Samuel J. Taylor et al. Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aam8060

Related Stories

New antibody uses 1-2 punch to potentially treat blood cancers

June 21, 2017
Researchers have developed a two-pronged approach to blood cancer treatment: 1) attacking cancer cells directly and/or 2) driving them from the nurturing bone marrow environment into the peripheral blood streams, where they ...

More than a third of high-risk leukemia patients respond to an experimental new drug

December 9, 2012
A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely ...

Inducing metabolic catastrophe in cancer cells

August 31, 2015
A study published in The Journal of Cell Biology describes a way to force cancer cells to destroy a key metabolic enzyme they need to survive.

Cannabinoids used in sequence with chemotherapy are a more effective treatment for cancer

June 5, 2017
New research has confirmed that cannabinoids - the active chemicals in cannabis - are effective in killing leukaemia cells, particularly when used in combination with chemotherapy treatments.

Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy

May 21, 2011
Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment. Researchers ...

Senescence promotes chemotherapy side effects and cancer relapse

January 17, 2017
Standard chemotherapy is a blunt force instrument against cancer – and it's a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, ...

Recommended for you

Early supper associated with lower risk of breast and prostate cancer

July 18, 2018
Having an early supper or leaving an interval of at least two hours before going to bed are both associated with a lower risk of breast and prostate cancer. Specifically, people who take their evening meal before 9 p.m. or ...

Scientists develop 'world first' melanoma blood test

July 18, 2018
Australian researchers said Wednesday they have developed a blood test for melanoma in its early stages, calling it a "world first" breakthrough that could save many lives.

Magnetized wire could be used to detect cancer in people, scientists report

July 16, 2018
A magnetic wire used to snag scarce and hard-to-capture tumor cells could prove to be a swift and effective tactic for early cancer detection, according to a study by researchers at the Stanford University School of Medicine.

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Researchers map 'family trees' of acute myeloid leukemia

July 16, 2018
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Scientists sharpen the edges of cancer chemotherapy with CRISPR

July 13, 2018
Tackling unsolved problems is a cornerstone of scientific research, propelled by the power and promise of new technologies. Indeed, one of the shiniest tools in the biomedical toolkit these days is the genome editing system ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.